ANEMIA OF INFLAMMATORY DISEASE IN THE DOG - AVAILABILITY OF STORAGE IRON IN INFLAMMATORY DISEASE

  • 1 January 1981
    • journal article
    • research article
    • Vol. 42  (4) , 586-589
Abstract
The Fe-chelating agent deferoxamine (DF) was administered as a single dose and also daily over a prolonged period to evaluate availability of storage Fe in dogs with induced anemia of inflammatory disease [AID]. In a 6 h period, total urinary ferrioxamine (measured as urinary Fe) excretion in controls was 251.22 .+-. 119.68 .mu.g (mean .+-. 1 SD), a 5.32 .+-. 2.64-fold increase over prechelation values. In AID-affected dogs, excretion was diminished to 115.67 .+-. 34.86 .mu.g, a 2.87 .+-. 1.10-fold increase, indicating a restricted Fe excretion and sequestration of Fe in a less soluble, less chelatable form. During prolonged DF administration, a pattern of increasing total urinary Fe excretion was observed. This pattern is consistent with Fe being stored as an insoluble polynuclear hydroxide in protein of ferritin and hemosiderin. The increase in Hb and serum Fe concentrations during prolonged DF administration indicates that increased Fe stores are present, but in a less labile form. During the process of chelation, Fe is converted to a more readily utilized state, and the increased Fe promotes Hb synthesis. Thus, storage Fe in the form of hemosiderin and ferritin is released to the metabolizable pool.